

Pleiotropic effects of sitagliptin versus voglibose in patients with type 2 diabetes inadequately controlled via diet and/or a single oral antihyperglycemic agent: a multicenter, randomized trial

Yukiko Matsushima,^{1,2,3} Yumie Takeshita,^{1,2,3} Yuki Kita,^{1,3} Toshiaki Otsuda,^{1,3} Ken-ichiro Kato,^{1,3} Hitomi Toyama-Wakakuri,^{1,3} Hiroshi Akahori,³ Akiko Shimizu,³ Erika Hamaguchi,³ Yasuyuki Nishimura,³ Takehiro Kanamori,^{1,3} Shuichi Kaneko,² Toshinari Takamura^{1,2,3}

To cite: Matsushima Y, Takeshita Y, Kita Y, *et al*. Pleiotropic effects of sitagliptin versus voglibose in patients with type 2 diabetes inadequately controlled via diet and/or a single oral antihyperglycemic agent: a multicenter, randomized trial. *BMJ Open Diabetes Research and Care* 2016;**4**:e000190. doi:10.1136/bmjdr-2015-000190

► Additional material is available. To view please visit the journal (<http://dx.doi.org/10.1136/bmjdr-2015-000190>).

YM, YT and TT contributed equally.

Received 24 December 2015
Revised 4 February 2016
Accepted 15 February 2016



CrossMark

For numbered affiliations see end of article.

Correspondence to

Professor Toshinari Takamura;
ttakamura@m-kanazawa.jp

ABSTRACT

Purpose: A step-up strategy for diet therapy and/or single oral antihyperglycemic agent (OHA) regimens has not yet been established. The aim of this study was to evaluate hemoglobin A1c (HbA1c) as a primary end point, and the pleiotropic effects on metabolic and cardiovascular parameters as secondary end points, of sitagliptin versus voglibose in patients with type 2 diabetes with inadequate glycemic control while on diet therapy and/or treatment with a single OHA.

Methods: In this multicenter, randomized, open-label, parallel-group trial, a total of 260 patients with inadequately controlled type 2 diabetes (HbA1c levels >6.9%) were randomly assigned to receive either sitagliptin (50 mg, once daily) or voglibose (0.6 mg, thrice daily) for 12 weeks. The primary end point was HbA1c levels.

Results: Patients receiving sitagliptin showed a significantly greater decrease in HbA1c levels ($-0.78 \pm 0.69\%$) compared with those receiving voglibose ($-0.30 \pm 0.78\%$). Sitagliptin treatment also lowered serum alkaline phosphatase levels and increased serum creatinine, uric acid, cystatin-C and homeostasis model assessment- β values. Voglibose increased low-density lipoprotein-cholesterol levels and altered serum levels of several fatty acids, and increased Δ -5 desaturase activity. Both drugs increased serum adiponectin. The incidence of adverse events (AEs) was significantly lower in the sitagliptin group, due to the decreased incidence of gastrointestinal AEs.

Conclusions: Sitagliptin shows superior antihyperglycemic effects compared with voglibose as a first-line or second-line therapy. However, both agents possess unique pleiotropic effects that lead to reduced cardiovascular risk in Japanese people with type 2 diabetes.

Trial registration number: UMIN 00003503.

Key messages

- This study directly compared a hemoglobin A1c and the pleiotropic effects of sitagliptin with voglibose added to concurrent treatment in Japanese patients with type 2 diabetes who could not achieve adequate glycemic control through diet therapy or a single OHA. Compared to voglibose, sitagliptin was superior to voglibose in lowering HbA1c levels in monotherapy and in combination therapy.
- Sitagliptin, but not voglibose, might impair renal function. Sitagliptin significantly increased serum Cre and cys-C decreased estimated glomerular filtration rate average.
- Sitagliptin significantly decreased polyunsaturated fatty acids, especially ω 6 fatty acids, whereas voglibose altered serum levels of many kinds of fatty acids. Voglibose, but not sitagliptin, increased Δ -5 desaturase activity. Both sitagliptin and voglibose exert significant unique pleiotropic effects on surrogate cardiovascular risks.

INTRODUCTION

Recent large-scale clinical trials have suggested that intensive antidiabetic therapies that cause unnecessary hyperinsulinemia do not achieve satisfactory cardiovascular outcomes in people with type 2 diabetes, as they may lead to hypoglycemia and weight gain.¹ To avoid these problems, incretin-based agents that do not provoke unnecessary hyperinsulinemia have been developed, and are generally used as second- or third-line therapies, in addition to metformin, in Western countries.² However, to date, limited

clinical evidence is available regarding incretin-based agents as first-line or second-line antihyperglycemic therapies.

Sitagliptin is an inhibitor of dipeptidyl peptidase-4 (DPP-4), which subsequently prevents enzymatic inactivation of endogenous glucagon-like peptide-1 (GLP-1)³ and thus improves glycemic control in type 2 diabetes. Sitagliptin has proven effective both as a monotherapy and in combination with other oral antihyperglycemic agents,^{4 5} although it is thought to be more effective in Asian patients than in Caucasian patients.⁶ However, the majority of studies on sitagliptin monotherapy and combination therapy are based on non-Japanese patients, and its pleiotropic effects have not been investigated extensively, especially in Japanese patients.

Voglibose is an α -glucosidase inhibitor widely used to improve postprandial hyperglycemia. The antidiabetic actions of voglibose may be mediated, at least in part, by endogenous incretins because an α -glucosidase inhibitor may increase GLP-1 levels both by inhibiting DPP-4 activity⁷ and by delaying intestinal absorption of a meal.⁸ However, the differences between sitagliptin and voglibose are unknown from the perspective of understanding pleiotropic effects.

The aim of this study was to evaluate hemoglobin A1c (HbA1c) as a primary end point, and the pleiotropic effects on metabolic and cardiovascular parameters as secondary end points, of sitagliptin versus voglibose in Japanese patients with type 2 diabetes who were unable to achieve adequate glycemic control via diet therapy and/or OHA monotherapy. Notably, dynamic randomization was used to adjust for demographic differences between the groups.

RESEARCH DESIGN AND METHODS

Overview

This was a randomized, parallel-group study conducted on Japanese patients. The study was designed in accordance with the principles stated in the Declaration of Helsinki, and the protocol was reviewed and approved by the appropriate institutional review board for each study site. All patients provided written informed consent before participation.

A total of 260 type 2 diabetes patients who were unable to achieve adequate glycemic control via diet therapy and/or OHA monotherapy were recruited from 19 centers in Japan between May 2011 and August 2012. Type 2 diabetes was diagnosed according to WHO criteria, based on a 2 h plasma glucose value of >11.1 mmol/L.⁹ Inadequate disease control was defined as having a HbA1c level $>6.9\%$. The trial was registered with the University Hospital Medical Information Network (UMIN) Clinical Trials Registry (registration number UMIN000003503).

Patient eligibility

Participants were eligible if they were at least 20 years old, had type 2 diabetes mellitus, poorly controlled

diabetes (HbA1c levels $>6.9\%$ within 12 weeks before screening), and had been treated with diet therapy and/or a single OHA, such as sulfonylurea (SU), biguanide (BG) or thiazolidinedione (TZD) class drugs, for 12 weeks or longer.

Exclusion criteria were: (1) hypersensitivity or a contraindication to sitagliptin or voglibose; (2) history of type 1 diabetes; (3) history of ketoacidosis; (4) having experienced symptoms of hypoglycemia; (5) treatment with sitagliptin or voglibose within 12 weeks before screening; (6) treatment with insulin within 12 weeks before screening; (7) concomitant corticosteroid therapy; (8) poorly controlled or unstable diabetes (the state with ketoacidosis or with an increase in HbA1c $>3\%$ in the 12 weeks before screening); (9) alanine aminotransferase and/or aspartate aminotransferase levels more than 2.5-fold the upper limit of normal; (10) poorly controlled hypertension or systolic blood pressure >160 mm Hg or diastolic blood pressure >100 mm Hg; (11) presence of a severe health problem not suitable for the study; (12) pregnancy or breastfeeding; or (13) inability to participate in the study due to psychiatric or psychosocial status as assessed by the investigators.

Efficacy endpoints

A computer-generated randomization sequence was used to assign participants in a 1:1 ratio to either the sitagliptin or voglibose treatment group. Dynamic randomization was used to adjust for demographic differences (age, previous treatment for type 2 diabetes and HbA1c level) between the groups. In this active-comparator, parallel-group trial, eligible patients received either sitagliptin or voglibose in addition to their previous treatment for 12 weeks. Sitagliptin (Merck & Co, Inc, New Jersey, USA) was initiated and maintained at 50 mg once daily. Voglibose (Takeda Pharmaceutical Company Limited, Osaka, Japan) was initiated and maintained at 0.6 mg (0.2 mg with each meal). Other medications were unchanged during the study period.

The primary efficacy end point was the change in HbA1c levels from baseline over the 12-week period. Secondary end points recorded at baseline and week 12 included: fasting plasma glucose (FPG); serum creatinine (Cre); uric acid; alkaline phosphatase (ALP), bone alkaline phosphatase (BAP), cystatin-C (cys-C), 1,5-anhydroglucitol (1,5-AG), fasting serum insulin (IRI), fasting serum proinsulin, fasting C-peptide immunoreactivity (CPR), factors related to fasting lipid profile (including small dense low-density lipoprotein, low-density lipoprotein-cholesterol, adiponectin, tumour necrosis factor α (TNF- α) and leptin); blood pressure; and physical measures (waist circumference, body mass index (BMI)). The estimated glomerular filtration rates based on serum Cre (eGFR_{creat}) and serum cys-C (eGFR_{cys}), and the average estimated glomerular filtration rate (eGFR_{average}), were calculated using the following formulas: $eGFR_{creat} = 194 \times Cr^{-1.094} \times Age^{-0.287}$

(males) or $194 \times Cr^{-1.094} \times Age^{-0.287} \times 0.739$ (females); $eGFR_{cys} = (104 \times Cystatin\ C^{-1.019} \times 0.996^{age}) - 8$ (males) or $(104 \times Cystatin\ C^{-1.019} \times 0.996^{age} \times 0.929) - 8$ (females); $eGFR_{average} = ((eGFR_{creat} + eGFR_{cys}) / 2)$.^{10 11} The homeostasis model assessment of insulin resistance (HOMA-IR) was used as a conventional index for insulin resistance and was calculated as $(IRI\ (U/mL) \times FPG\ (mmol/L)) / 22.5$.¹²

To assess basic insulin secretion by β cells, CPR index (CPI), homeostasis model assessment- β (HOMA- β), secretory unit of islet in transplantation index (SUIT index) and quantitative insulin sensitivity check index (QUICKI), were calculated as follows: $CPI = (100 \times \text{fasting CPR (ng/mL)}) / FPG\ (mg/dL)$,¹³ $HOMA-\beta = (IRI\ (IU/L) \times 20) / (FPG\ (mg/dL) - 63)$,¹⁴ $SUIT\ index = (1500 \times CPR\ (ng/mL)) / (FPG\ (mg/dL) - 63)$ ¹⁵ and $QUICKI = (1 / (\log\ IRI\ (IU/L) + \log\ FPG\ (mg/dL)))$.¹⁶

Serum fatty acid levels were measured as a secondary outcome. A serum sample (approximately 0.2 mL) and 2 mL of a chloroform-methanol solution (2:1) were placed in a Pyrex centrifuge tube, homogenized with a Polytron homogenizer (PCU-2-110; KINEMATICA GmbH, Switzerland) and centrifuged at 3000 rpm for 10 min. An aliquot of the chloroform-methanol extract was transferred to another Pyrex tube and dried under a stream of nitrogen gas. The dried sample was dissolved in 100 μ L of 0.4 M potassium methoxide methanol/14% boron trifluoride-methanol solution, and the fatty acid concentrations were measured at SRL Inc (Tokyo, Japan), using a gas chromatograph (Shimizu GC 17A, Kyoto, Japan). Desaturase activities were estimated as follows: Δ -5 desaturase, $C20:4\omega6 / C20:3\omega6$; Δ -6 desaturase, $18:3\omega6 / 18:2\omega6$.¹⁷

Medication adherence and adverse events were monitored throughout the study, and were rated by investigators for intensity and relationship to study drug.

Statistical analysis

The sample size required to detect a -0.6% change in HbA1c levels in the sitagliptin group, and a -0.4% change in the voglibose group, with a power of 80% ($\alpha=0.05$, one-tailed; $\beta=0.20$) and standardized effect size of 0.6, was 112 participants in each group. Taking into account a dropout rate of 15%, we aimed to recruit 260 participants. All analyses used the full analysis set, which included all patients who received at least one dose of study drug and for whom data were available at baseline and from at least one postrandomization time point. Missing data were replaced by the last observed value of each variable in this analysis. Data were expressed as the mean \pm SD. The Statistical Package for the Social Sciences (SPSS) V.22.0 (SPSS Inc, Chicago, Illinois, USA) was used for the statistical analyses. Parameters were analyzed using the Wilcoxon signed-rank test in the internal group comparison, the χ^2 test or the Mann-Whitney *U*-test, or the Kruskal-Wallis test, in the intergroup comparison. Associations between variables were assessed using Spearman's rank correlation coefficient. Multiple

regression analysis was carried out to determine independent factors for changes in HbA1c by sitagliptin or voglibose. *p* Values <0.05 were considered statistically significant.

RESULTS

Patient characteristics

A total of 260 patients were screened and randomly assigned to either the sitagliptin or voglibose regimen, and 241 participants (mean age, 63.2 ± 12.7 years; mean BMI, 25.0 ± 4.5 kg/m²) were enrolled in this study (table 1). Nineteen patients were removed after randomisation before the intervention because they withdrew consent ($n=17$) or did not meet inclusion criteria ($n=2$; see online supplementary figure S1). No participants took EPA or docosahexaenoic acid (DHA) before or during the study and other subject medications remained unchanged during the study period. One hundred and sixteen patients received diet therapy, 61 patients received SU, 57 patients received BG and seven patients received TZD. FPG and HbA1c levels were 154.7 ± 35.1 mg/dL and $7.9 \pm 0.9\%$, respectively. Baseline demographics and disease characteristics of the two groups did not differ significantly (table 1). The serum TNF- α levels at baseline included two outliers in the sitagliptin group. The median was similar in the two groups (Sitagliptin versus Voglibose, 1.20 vs 1.10 (pg/mL)) and there was no significant difference in the Mann-Whitney *U* test ($p=0.166$).

Clinical outcomes

Compared to baseline, FPG and HbA1c levels decreased significantly in both groups at the end of the study (table 2). Sitagliptin was superior to voglibose in lowering HbA1c levels (-0.78 ± 0.69 vs $-0.30 \pm 0.78\%$, respectively) and FPG concentrations (-16.2 ± 26.4 vs -4.4 ± 38.7 mg/dL, respectively) relative to baseline. There was no significant difference of medication adherence between the groups (table 1). In addition, in the stratified analysis on good ($\geq 80\%$) and poor ($<80\%$) adherence, adherence rate did not affect these results (see online supplementary table S1).

Both agents significantly increased 1,5-AG concentrations, but voglibose was superior to sitagliptin in this regard. Sitagliptin, but not voglibose, increased indices for insulin secretion such as HOMA- β , SUIT and CPI. Both agents lowered proinsulin levels and both agents exerted marked effects on the insulin sensitivity index, QUICKI.

Sitagliptin significantly reduced the counts of lymphocytes ($p=0.007$) and significantly increased the counts of neutrophils ($p=0.008$) at week 12, whereas voglibose had no effect on them (table 2). Sitagliptin significantly lowered ALP levels from 236 ± 71 IU/L at baseline to 226 ± 76 IU/L at week 12 ($p=0.000$) without changing bone alkaline phosphatase (BAP), whereas voglibose had no effect on ALP levels. Both agents were almost neutral in their effects on liver enzymes, except that voglibose

Table 1 Characteristic of the study participants

	All (n=241)	Sitagliptin (n=120)	Voglibose (n=121)	p Value
Male/Female	143/98	72/48	71/50	0.603
Age (years)	63.2±12.7	63.2±13.8	63.2±11.6	0.699
Medication adherence rate (≥80%/<80%)	193/48	99/21	94/27	0.420
Combination therapy (Diet/SU/BG/TZD)	116/61/57/7	59/29/29/3	57/32/28/4	0.953
Body weight (kg)	64.8±14.4	63.8±13.6	65.8±15.1	0.515
BMI (kg/m ²)	25.0±4.5	25.0±4.5	25.1±4.5	0.984
Waist circumference (cm)	89.9±11.1	88.7±10.5	91.0±11.7	0.162
Systolic BP (mm Hg)	130.8±17.7	130.0±16.8	131.6±18.5	0.413
FPG (mg/dL)	154.7±35.1	156.3±35.1	153.2±35.2	0.347
HbA1c (%)	7.9±0.9	7.9±1.0	7.8±0.8	0.935
1.5AG (µg/mL)	6.9±4.8	6.5±4.2	7.4±5.3	0.429
BUN (mg/dL)	15.1±4.5	14.9±4.1	15.2±4.9	0.886
s-Cre (mg/dL)	0.72±0.23	0.70±0.19	0.74±0.27	0.870
AST (IU/L)	26±14	26±13	26±16	0.823
ALT (IU/L)	31±25	32±25	30±25	0.522
γ-GTP (IU/L)	46±53	44±49	49±57	0.072
TC (mg/dL)	188.4±33.0	185.1±33.4	191.6±32.4	0.130
TG (mg/dL)	140.1±93.6	136.0±83.1	144.2±103.1	0.899
HDL-C (mg/dL)	53.8±16.7	52.7±15.4	54.9±18.0	0.250
LDL-C (mg/dL)	106.2±28.1	105.0±29.6	107.5±26.5	0.234

Data are expressed as means±SD. p Value for the intergroup comparison.

AG, anhydroglucitol; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BG, biguanide; BMI, body mass index; BP, blood pressure; BUN, blood urea nitrogen; FPG, fasting plasma glucose; HbA1c, hemoglobin A1c; HDL-c, low-density lipoprotein cholesterol; LDL-C, low-density lipoprotein-cholesterol; s-Cre, serum creatinine; SU, sulfonylurea; TC, total cholesterol; TG, triglyceride; TZD, thiazolidinedione; γ-GTP, γ-glutamyl transpeptidase.

treatment decreased γ-GTP levels from 49±57 IU/L at baseline to 47±51 IU/L at week 12 (p=0.011). Sitagliptin, but not voglibose, increased serum Cre, uric acid and cys-C. Both agents lowered serum triglyceride levels, whereas voglibose, but not sitagliptin, significantly increased LDL-C. Voglibose significantly increased TNF-α levels, whereas sitagliptin, rather, tended to decrease TNF-α levels. Both agents significantly increased adiponectin levels. In stratified analyses on each concomitant therapy, there was no significant difference in glycemic parameters (see online supplementary figure S2). SU significantly increased neutrophils and decreased diastolic blood pressure compared to BG in the sitagliptin group (data not shown).

Factors predicting the effects of sitagliptin and voglibose are shown in table 3. In the sitagliptin group, there was a significant correlation between ΔHbA1c and baseline levels of 1,5-AG (rs=0.338, p=0.000), HbA1c (rs=-0.589, p=0.000) and adiponectin (r=0.223, p=0.015; table 3). There was no predicting factor in the voglibose group. In a multiple regression analysis, only baseline HbA1c was the independent factor of ΔHbA1c in the sitagliptin group (β=-0.0525, p=0.000, adjusted R²=0.268).

Changes in fatty acid composition in serum lipids

Sitagliptin, but not voglibose, significantly decreased serum levels of total polyunsaturated fatty acids, including linoleic acid and total ω6 fatty acids. Voglibose, but not sitagliptin, significantly decreased total saturated fatty acids (including palmitic acid and stearic acid), total monounsaturated fatty acids (including palmitoleic

acid and oleic acid) and some polyunsaturated fatty acids (such as γ-linolenic acid, 5,8,11-eicosatrienoic acid, dihomo-γ-linolenic acid, docosatetraenoic acid and docosapentaenoic acid). Voglibose significantly decreased the activity of Δ-6 desaturase and increased that of Δ-5 desaturase (table 4). No correlation was observed between ΔHbA1c and eicosapentaenoic acid (EPA) levels at baseline in the sitagliptin group (table 3).

Adverse events

The incidence of AEs was significantly lower in the sitagliptin group. This difference was attributable to the decreased incidence of gastrointestinal AEs, such as heartburn, abdominal pain, constipation, loose stool, diarrhea, meteorism and flatulence. Most AEs were mild or moderate but one patient in the voglibose group discontinued the treatment due to diarrhea. The incidence of hypoglycemia was low and similar in both groups. All incidences of hypoglycemia in this study were mild or moderate in severity, but one patient in the sitagliptin group discontinued the treatment due to hypoglycemia. Four serious adverse events (SAEs)—inguinal hernia, heart failure, pancreatitis and urinary tract infection—occurred in the voglibose group, but were considered not related to the study. Due to these SAEs, three patients discontinued the agents (see online supplementary table S2).

DISCUSSION

This study directly compared HbA1c and the pleiotropic effects of sitagliptin with voglibose added to concurrent

Table 2 Changes in the characteristics of patients between baseline and 12 weeks

Parameter	n	Sitagliptin			p Value*	n	Voglibose			p Value†
		Baseline	12-week				Baseline	12-week		
Body weight (kg)	120	63.8±13.6	63.7±13.3	0.842	120	65.8±15.2	65.3±15.1	0.025	0.126	
BMI	118	24.9±4.5	24.9±4.4	0.777	119	25.1±4.5	24.9±4.4	0.024	0.086	
Waist (cm)	116	88.7±10.5	88.2±10.0	0.195	120	91.0±11.7	90.0±11.1	0.013	0.363	
SBP (mm Hg)	120	130.0±16.8	129.5±17.1	0.998	121	131.6±18.5	128.9±16.7	0.067	0.265	
DBP (mm Hg)	120	76.0±12.1	75.4±12.1	0.576	121	75.1±12.9	74.4±12.5	0.689	0.918	
WBC (/mm ³)	120	5815±1362	6057±1590	0.050	119	5985±1762	5940±1975	0.315	0.037	
Neutrophils (/mm ³)	108	3279±1015	3570±1096	0.008	107	3485±1313	3431±1587	0.193	0.007	
Eosinophils (/mm ³)	105	156±120	151±120	0.000	105	163±108	164±114	0.821	0.074	
Basophils (/mm ³)	105	30±23	31±23	0.359	105	32±21	34±28	0.864	0.247	
Lymphocytes (/mm ³)	105	1951±607	1866±586	0.007	105	2041±723	2023±766	0.772	0.023	
Monocytes (/mm ³)	105	323±113	345±122	0.004	105	339±139	340±150	0.270	0.009	
PLT (10 ⁴ /mm ³)	120	21.0±5.5	20.8±5.6	0.281	119	21.8±6.0	21.3±5.8	0.084	0.574	
RBC (10 ³ /mm ³)	120	458.4±43.7	459.2±45.4	0.723	119	454.1±52.1	457.2±50.3	0.124	0.612	
Hb (g/mL)	120	13.9±1.6	14.0±1.8	0.943	119	13.9±1.6	14.0±1.5	0.548	0.882	
Ht (%)	120	41.6±4.1	41.7±4.4	0.565	119	41.3±4.2	41.8±4.0	0.030	0.399	
AST (IU/L)	120	26±13	26±13	0.554	120	26±16	25±11	0.961	0.776	
ALT (IU/L)	120	32±25	30±21	0.459	120	30±26	30±20	0.505	0.309	
ALP (IU/L)	120	236±71	226±76	0.000	118	237±91	236±101	0.168	0.074	
BAP (µg/L)	116	12.6±5.6	12.3±5.6	0.140	116	12.7±5.5	12.5±4.9	0.832	0.186	
γ-GTP (IU/L)	120	44±50	49.2±87.6	0.836	119	49±57	47±51	0.011	0.051	
CK (IU/L)	117	105.5±71.6	105.2±68.0	0.920	116	109.2±59.5	107.4±54.5	0.552	0.720	
BUN (mg/dL)	120	14.9±4.1	15.0±4.6	0.838	120	15.3±4.9	14.5±4.9	0.041	0.166	
Cr (mg/dL)	120	0.71±0.19	0.74±0.19	0.000	120	0.74±0.27	0.76±0.27	0.129	0.199	
UA (mg/dL)	119	5.08±1.14	5.30±1.24	0.001	120	5.13±1.40	5.28±1.40	0.073	0.328	
Cystatin C (mg/L)	114	0.82±0.18	0.85±0.19	0.001	112	0.86±0.23	0.86±0.23	0.177	0.087	
eGFRcreat (mL/min/1.73 m ²)	120	85.0±28.4	80.6±26.5	0.000	120	80.4±24.1	78.3±23.4	0.069	0.203	
eGFRcys (mL/min/1.73 m ²)	114	91.1±23.2	91.1±29.3	0.969	112	87.9±25.0	88.5±22.9	0.626	0.132	
eGFRaverage (mL/min/1.73 m ²)	114	88.0±23.3	85.6±24.6	0.006	111	83.7±22.2	83.4±20.8	0.687	0.053	
TC (mg/dL)	120	185.1±33.4	184.9±39.0	0.910	118	191.6±32.4	193.6±40.8	0.066	0.272	
HDL-C (mg/dL)	118	52.7±15.4	52.3±14.8	0.873	118	54.9±18.0	54.8±18.3	0.739	0.712	
Triglyceride (mg/dL)	120	136.0±83.1	129.8±85.5	0.098	120	144.2±103.2	129.3±79.0	0.015	0.450	
LDL-C (mg/dL)	118	104.9±29.6	106.5±34.1	0.499	117	107.5±26.5	112.7±36.5	0.001	0.026	
sdLDL (mg/dL)	118	36.8±15.4	34.9±15.1	0.134	120	38.0±16.6	38.3±17.6	0.831	0.220	
IRI (IU/L)	116	8.46±8.20	8.69±9.37	0.342	118	14.1±65.1	14.2±69.5	0.028	0.039	
CPR (ng/mL)	118	2.10±0.88	2.04±0.84	0.421	120	2.08±1.03	2.05±1.13	0.634	0.715	
HMW adiponectin (µg/dL)	118	3.17±2.30	3.50±2.57	0.000	120	3.53±3.65	3.74±3.53	0.000	0.161	
Hypersensitive TNF-α (pg/mL)	118	3.11±12.47	2.23±5.21	0.079	120	1.42±1.87	1.55±1.83	0.000	0.538	
Leptin (ng/mL)	118	8.26±6.90	8.27±7.17	0.561	120	9.02±9.28	8.21±6.59	0.694	0.540	
HOMA-IR	115	3.30±3.44	2.98±3.02	0.056	117	5.21±23.02	5.52±29.02	0.003	0.443	
HOMA-β	115	36.0±32.8	47.2±57.6	0.000	117	63.7±299.6	59.5±237.4	0.408	0.002	
SUIT index	117	39.5±30.4	45.9±28.3	0.000	118	38.0±22.1	40.9±23.8	0.004	0.047	

Continued

Table 2 Continued

Parameter	Sitagliptin			Voglibose		
	n	Baseline	12-week	n	Baseline	12-week
CPI	117	1.41±0.67	1.52±0.71	118	1.38±0.68	1.43±0.78
QUICKI	112	0.34±0.04	0.34±0.04	116	0.34±0.05	0.34±0.05
Proinsulin (pM)	112	26.9±17.2	22.5±14.3	104	26.5±17.9	25.3±17.4
Proinsulin/Insulin Ratio	101	0.70±0.67	0.54±0.33	91	0.63±0.39	0.65±0.49
HbA1c (%)	120	7.94±1.03	7.15±0.88	121	7.86±0.78	7.56±1.02
1.5AG (µg/mL)	109	6.45±4.16	10.55±5.96	105	7.43±5.29	12.6±8.12
FPG (mg/dL)	119	156.3±35.1	140.0±31.7	119	153.2±35.2	148.0±43.0

Data are expressed as means±SD.

*p Value for the intragroup comparison (baseline vs 12 weeks).

†p Value for the intergroup comparison (difference in changes from baseline between groups).

ALT, alanine aminotransferase; ALP, alkaline phosphatase; AST, aspartate aminotransferase; BAP, bone alkaline phosphatase; BMI, body mass index; BUN, blood urea nitrogen; CK, creatinine kinase; CPI, CPR index; CPR, C-peptide immunoreactivity; Cr, creatinine; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; FPG, fasting plasma glucose; Hb, hemoglobin; HDL-c, low-density lipoprotein cholesterol; HMM, high molecular weight; HOMA-IR, homeostasis model assessment of insulin resistance; HOMA-β, homeostasis model assessment-β; IRI, fasting serum insulin; LDL-C, low-density lipoprotein-cholesterol; PLT, platelet; QUICKI, quantitative insulin sensitivity check index; RBC, red blood cell; SBP, systolic blood pressure; sLDL, small dense low-density lipoprotein; SUT, secretory unit of islet in transplantation index; TC, total cholesterol; TNF-α, tumour necrosis factor α; UA, uric acid; WBC, white blood cell count.

treatment in Japanese patients with type 2 diabetes who could not achieve adequate glycemic control through diet therapy or a single OHA. The novelty of the present study is as follows: First, dynamic randomization is methodologically novel. It is useful to adjust for demographic differences between each group. In this open-label, randomized, parallel-group study with dynamic allocation, we compared sitagliptin with voglibose, not only as a monotherapy, but also as an add-on therapy to SU, BG or TZD. Second, pleiotropic effects of sitagliptin and voglibose include previously yet-recognized findings.

Regarding the primary endpoint, sitagliptin was superior to voglibose in lowering HbA1c levels in monotherapy and in combination with each concurrent agent. A similar reduction in HbA1c was also observed in previous 12-week studies.^{18–20}

Regarding the secondary end points, sitagliptin and voglibose exerted unique pleiotropic effects in the present study. Sitagliptin, but not voglibose, significantly increased the markers of β-cell function (HOMA-β and proinsulin/insulin ratio). Preclinical studies have shown that GLP-1 stimulates β-cell differentiation and proliferation, inhibits apoptosis of β-cells,^{21 22} and stimulates β-cell neogenesis and survival in streptozotocin-treated rats.²³ In fact, several reviews have indicated that DPP-4 inhibitors consistently improve markers of β-cell function in type 2 diabetes patients.^{20 24 25} A decrease in the fasting proinsulin-to-insulin ratio, consistent with improved β-cell function, was observed in association with sitagliptin treatment in a previous study.²⁶

Sitagliptin compared with voglibose significantly reduced the counts of lymphocytes and increased those of neutrophils in the present study, as observed in the previous study.²⁷ DPP-4 is highly expressed by T-cells, especially CD4+ T-cells. Sitagliptin decreases CD4+ T-cells in a glucose-independent manner.²⁷ Whether DPP-4 inhibitors suppress immunity by reducing the number of circulating CD4+ T-cells should be examined in future. Sitagliptin significantly increased serum levels of Cre, cys-C and uric acid, and decreased eGFRcreat, whereas voglibose had no effect on these parameters in the present study. These results might relate to the Na-diuretic action of GLP-1,²⁸ although we observed no reduction in blood pressure in the present study. Therefore, it is possible that sitagliptin impairs renal function. In fact, during a much longer, 54-week study, it was found that 18.8% of patients in the sitagliptin group with moderate renal insufficiency at baseline transitioned to severe renal insufficiency status over the course of the study.²⁹ On the other hand, in our study, deterioration of eGFRcys was not observed. After 12 weeks, sitagliptin, but not voglibose, decreased ALP levels relative to baseline without affecting BAP levels. Although it is not certain whether this sitagliptin-mediated decrease in ALP is related to bone metabolism, the decrease in ALP from baseline significantly correlated with a decrease in HbA1c levels, as observed in previous studies.^{30 31}

Table 3 Factors associated with a change in HbA1c

	Sitagliptin		Voglibose	
	rs	p Value	rs	p Value
Baseline				
Body weight (kg)	-0.051	0.577	-0.082	0.374
Body mass index	-0.142	0.126	-0.08	0.390
Fasting plasma glucose (mg/dL)	-0.113	0.222	0.107	0.246
1,5 AG (%)	0.338	0.000	-0.034	0.714
HbA1c (%)	-0.589	0.000	-0.121	0.185
Total cholesterol (mg/dL)	0.050	0.588	0.009	0.948
Fasting serum insulin (IU/L)	-0.092	0.328	-0.079	0.392
CPR (ng/mL)	-0.101	0.275	-0.004	0.965
HMW adiponectin (μ g/mL)	0.223	0.015	0.137	0.137
CPI	-0.048	0.609	-0.038	0.684
HOMAIR	-0.128	0.171	0.114	0.222
HOMA- β	-0.016	0.861	0.033	0.722
EPA (ng/mL)	-0.064	0.490	0.062	0.502
DHA (ng/mL)	-0.077	0.118	-0.078	0.396
Change from baseline				
Δ FPG	0.386	0.000	0.421	0.000
Δ BW	0.212	0.020	0.047	0.609
Δ BMI	0.206	0.025	0.058	0.533
Δ ALP	0.269	0.003	0.187	0.042
Δ TC	0.231	0.011	-0.062	0.502
Δ LDLC	0.266	0.004	0.151	0.103
Δ TG	0.084	0.362	-0.152	0.098
Δ HMW adiponectin	-0.310	0.001	-0.346	0.000
Δ HOMA-IR	0.233	0.012	0.105	0.262
Δ HOMA- β	-0.304	0.001	-0.222	0.016
Δ SUIT index	-0.377	0.000	-0.261	0.004
Δ QUICKI	-0.185	0.047	-0.175	0.060
Δ CPI	-0.235	0.011	-0.156	0.091
Δ Proinsulin insulin ratio	0.199	0.046	0.177	0.094
Δ EPA	-0.010	0.914	-0.062	0.502
Δ DHA	0.073	0.430	-0.065	0.482

AG, anhydroglucitol; ALP, alkaline phosphatase; BMI, body mass index; BW, body weight; CPR, C-peptide immunoreactivity; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; FPG, fasting plasma glucose; HbA1c, hemoglobin A1c; HOMA-IR, homeostasis model assessment of insulin resistance; HOMA- β , homeostasis model assessment- β ; HMW, high molecular weight; LDLC, low-density lipoprotein cholesterol; TC, total cholesterol; TG, triglyceride.

Both sitagliptin and voglibose significantly increased plasma adiponectin levels, as stated in previous reports.^{32–33} There was a negative correlation between Δ HbA1c and Δ adiponectin (table 3), suggesting that glycemic control at least partly contributes to the increase in adiponectin levels. The increased adiponectin levels might improve endothelial function and likely yield anti-atherosclerotic effects.³⁴ In addition, baseline levels of adiponectin were negatively correlated with Δ HbA1c only in the sitagliptin group, suggesting that adiponectin level might be a predictive maker for the effect of sitagliptin in glycemic control. Serum EPA concentrations are reported to be associated with the glucose-lowering effect of DPP-IV inhibitors in Japanese patients with type 2 diabetes.³⁵ However, in our study, baseline EPA levels were not correlated with the change in HbA1c in the sitagliptin group (table 3). On the other hand, sitagliptin significantly decreased polyunsaturated fatty acids, especially ω 6 fatty acids, whereas voglibose altered serum

levels of many kinds of fatty acids, unlike in a previous study with acarbose.³⁶ Notably, voglibose, but not sitagliptin, increased Δ -5 desaturase activity. Several cross-sectional studies showed that the Δ -5 desaturase activity index, which refers to the ratio of arachidonic acids to dihomo- γ -linolenic acids, is positively associated with insulin sensitivity^{37–38} and the onset of newly diagnosed type 2 diabetes,³⁹ and is negatively associated with several metabolic risk factors in patients with metabolic syndrome.⁴⁰ High Δ -5 desaturase activity was associated with reduced coronary heart disease risk.⁴¹ Conversely, voglibose decreased Δ -6 desaturase activity. Δ -6 desaturase activity was associated with an increased probability of metabolic syndrome.⁴⁰ These findings suggest the possibility that voglibose, rather than sitagliptin, might reduce coronary heart disease risk by altering fatty acids profiling. However, as a limitation, because the present 3-month, open-label study was designed to compare the antihyperglycemic effects of sitagliptin and voglibose,

Table 4 Changes in plasma fatty acid composition between baseline and 12 weeks

Parameter		n	Sitagliptin			Voglibose				
			Baseline	12-week	p Value*	n	Baseline	12-week	p Value*	p Value†
Lauric acid	C12:0 (ng/mL)	118	2.3±2.2	2.3±2.3	0.555	120	2.5±2.1	2.2±2.3	0.139	0.592
Myristic acid	C14:0 (ng/mL)	118	29.9±18.9	28.5±19.3	0.147	120	33.1±23.0	30.0±22.8	0.012	0.356
Palmitic acid	C16:0 (ng/mL)	118	746.7±259.6	709.8±254.1	0.019	120	796.9±268.7	747.9±265.4	0.001	0.494
Palmitoleic acid	C16:1ω7 (ng/mL)	118	80.3±46.2	77.0±51.6	0.130	120	89.7±51.6	82.0±53.7	0.000	0.049
Stearic acid	C18:0 (ng/mL)	118	214.7±53.6	212.0±28.7	0.532	120	224.2±57.7	218.2±61.8	0.033	0.291
Oleic acid	C18:1ω9 (ng/mL)	118	656.2±236.6	653.2±260.1	0.799	120	714.9±295.4	671.7±268.3	0.049	0.194
Linoleic acid	C18:2ω6 (ng/mL)	118	774.4±182.1	736.3±188.6	0.021	120	798.6±208.2	807.2±244.4	0.902	0.143
γ-linolenic acid	C18:3ω6 (ng/mL)	118	11.4±6.5	10.8±6.0	0.941	120	11.9±6.9	10.2±5.5	0.000	0.023
α-Linolenic acid	C18:3ω3 (ng/mL)	118	27.6±12.5	25.9±11.1	0.010	120	27.3±15.0	27.2±16.3	0.331	0.164
Arachidic acid	C20:0 (ng/mL)	118	7.2±1.3	7.3±1.6	0.876	120	7.6±1.6	7.7±1.7	0.935	0.935
Eicosenoic acid	C20:1ω9 (ng/mL)	118	5.5±2.0	5.3±2.2	0.562	120	6.1±6.8	6.3±6.9	0.306	0.274
Eicosadienoic acid	C20:2ω6 (ng/mL)	118	5.9±1.8	5.9±2.0	0.599	120	6.3±2.0	6.3±2.1	0.764	0.929
5-8-11Eicosatrienoic acid	C20:3ω9 (ng/mL)	118	2.2±1.4	2.2±1.6	0.549	120	2.8±2.6	2.5±2.4	0.008	0.116
Dihomo-γ-linolenic acid	C20:3ω6 (ng/mL)	118	38.8±13.2	39.7±16.4	0.260	120	42.4±15.5	39.9±12.7	0.005	0.010
Arachidonic acid	C20:4ω6 (ng/mL)	118	173.2±48.7	172.0±51.3	0.706	120	184.5±46.5	183.5±44.6	0.691	0.898
Eicosapentaenoic acid	C20:5ω3 (ng/mL)	118	80.6±48.3	79.7±43.5	0.884	120	81.2±70.0	85.5±78.4	0.659	0.955
Behenic acid	C22:0 (ng/mL)	118	17.9±3.3	17.9±3.6	0.838	120	32.1±3.7	19.1±4.3	0.465	0.651
Erucic acid	C22:1ω9 (ng/mL)	118	1.6±0.8	1.6±0.7	0.613	120	1.8±0.9	1.7±0.9	0.768	0.291
Docosatetraenoic acid	C22:4ω6 (ng/mL)	118	5.2±2.2	5.1±2.6	0.248	120	5.5±2.3	5.1±1.9	0.011	0.306
Docosapentaenoic acid	C22:5ω3 (ng/mL)	118	25.2±10.0	24.3±9.4	0.399	120	25.8±13.1	24.0±13.5	0.004	0.955
Lignoceric acid	C24:0 (ng/mL)	118	16.3±2.8	16.3±3.3	0.775	120	17.5±3.4	17.8±3.9	0.423	0.598
Docosahexaenoic acid	C22:6ω3 (ng/mL)	118	175.2±65.3	169.5±58.7	0.305	120	175.2±94.5	167.7±96.1	0.095	0.531
Nervonic acid	C24:1ω9 (ng/mL)	118	34.8±7.5	34.5±7.5	0.357	120	37.0±8.2	37.7±8.0	0.028	0.028
EPA+DHA	(ng/mL)	118	255.9±107.5	249.2±92.6	0.536	120	256.3±160.3	253.1±169.4	0.436	0.782
EPA/AA ratio		118	0.49±0.31	0.49±0.30	0.705	120	0.44±0.32	0.044±0.32	0.435	0.895
Total ω3 fatty acids	(ng/mL)	118	308.7±121.9	299.0±105.3	0.370	120	309.4±181.0	304.3±191.6	0.308	0.735
Total ω6 fatty acids	(ng/mL)	118	1008.7±224.8	969.8±237.7	0.024	120	1049.2±238.2	1052.3±273.9	0.684	0.239
Total ω9 fatty acids	(ng/mL)	118	700.2±239.2	696.8±263.6	0.794	120	762.6±300.8	720.0±272.5	0.053	0.210
ω3/ω6 ratio		118	0.32±0.13	0.32±0.11	0.236	120	0.30±0.14	0.30±0.14	0.409	0.151
Total saturated fatty acids	(ng/mL)	118	1034.9±330.7	994.1±330.3	0.050	120	1101.1±346.5	1043.0±348.1	0.002	0.515
Monounsaturated fatty acids	(ng/mL)	118	778.3±276.8	771.7±305.2	0.762	120	854.3±346.8	799.5±306.6	0.020	0.132
Polyunsaturated fatty acids	(ng/mL)	118	1319.5±277.3	1270.9±289.2	0.014	120	1361.4±336.2	1359.0±384.4	0.562	0.233
δ-5desaturase (20:4 ω6/20:3 ω6)		118	4.73±1.42	4.72±1.62	0.595	120	4.78±1.77	4.97±1.64	0.014	0.031
δ-6desaturase (18:3 ω6/18:2 ω6)		118	0.015±0.008	0.015±0.007	0.321	120	0.016±0.01	0.014±0.009	0.009	0.007

Data are expressed as means±SD.

*p Value for the intragroup comparison (baseline vs 12 weeks).

†p Value for the intergroup comparison (difference in changes from baseline between groups).

AA, arachidonic acid; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid.

the study duration may be insufficient to evaluate some of the pleiotropic effects. In the subgroup analysis, concomitant antidiabetic agents did not affect the results in glycemic parameters.

In summary, we showed that sitagliptin is superior to voglibose in terms of improving glycemic control as a first/second-line therapy in Japanese people with type 2 diabetes. However, both agents exert unique pleiotropic effects on surrogate cardiovascular risks, which suggests a theoretical basis for potential benefits through combined therapy. A large-scale clinical trial on cardiovascular events is required to test this hypothesis.

Author affiliations

¹Department of Endocrinology and Metabolism, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Ishikawa, Japan

²Department of Disease Control and Homeostasis, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Ishikawa, Japan

³ERA-DM Chapter 1 Study Group, Kanazawa, Ishikawa, Japan

Collaborators Clinical Centres for the ERA-DM study Chapter 1 group: Department of Disease Control and Homeostasis, Kanazawa University Graduate School of Medical Science (Kanazawa, Ishikawa), Municipal Tsuruga Hospital (Tsuruga, Fukui), Koshino Hospital (Kanazawa, Ishikawa), Ishida Hospital (Kanazawa, Ishikawa), Handa Medical Clinic (Kanazawa, Ishikawa), Yumie Takeshita, MD PhD, Toshinari Takamura, MD PhD, Toshiaki Otoda, MD PhD; Ken-ichiro Kato MD, Hitomi Wakakuri, MD, Masayuki Yamada, MD, Hirofumi Misu, MD PhD, Shuichi Kaneko, MD PhD, Tsuguhito Ota, MD PhD, Takehiro Kanamori, MD, Yukiko Matsushima (coordinator), Shima Kitakata (coordinator); Public Hakui Hospital (Hakui, Ishikawa), Toshiaki Otoda, MD PhD; Japanese Red Cross Kanazawa Hospital (Kanazawa, Ishikawa), Erika Hamaguchi, MD PhD, Yasuyuki Nishimura, MD PhD; Toyama City Hospital (Toyama, Toyama), Akiko Shimizu, MD PhD; Public Central Hospital of Matto Ishikawa (Matto, Ishikawa), Yuki Kita, MD PhD, Kozo Kawai, MD PhD; Kahoku Central Hospital (Kahoku, Ishikawa), Kensuke Mouri, MD; Fukui Saiseikai Hospital (Fukui, Fukui), Kosuke R Shima, MD, Yukihiro Bando, MD PhD; Kanazawa Municipal Hospital (Kanazawa, Ishikawa), Nobuhiko Koike, MD PhD.

Contributors TT is the guarantor of this study and, as such, had full access to all of the data, and takes responsibility for the integrity and accuracy of the data and the analysis. YM designed the study, analysed and interpreted the data, and wrote the manuscript. YT designed the study, recruited the patients, collected clinical information, analysed and interpreted the data, and wrote the manuscript. YK, TO, KK, HT-W, HA, AS, EH, YN and TK collected clinical information. SK initiated and organized the study. All the authors have read and approved the final manuscript.

Funding This work was supported by Grants-in-Aid from the Ministry of Education, Culture, Sports, Science, and Technology of Japan, and Research grants from ONO Pharmaceutical Co, Ltd (to TT and SK).

Competing interests None declared.

Patient consent Obtained.

Ethics approval Kanazawa University Hospital Institutional Review Board.

Provenance and peer review Not commissioned; externally peer reviewed.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

REFERENCES

- Ray KK, Seshasai SRK, Wijesuriya S, *et al*. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. *Lancet* 2009;373:1765–72.
- Inzucchi SE, Bergenstal RM, Buse JB, *et al*. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care* 2012;35:1364–79.
- Kirby M, Yu DMT, O'Connor S, *et al*. Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition. *Clin Sci (Lond)* 2010;118:31–41.
- Karasik A, Aschner P, Katzeff H, *et al*. Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials. *Curr Med Res Opin* 2008;24:489–96.
- Raz I, Hanefeld M, Xu L, *et al*. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. *Diabetologia* 2006;49:2564–71.
- Iwamoto Y, Taniguchi T, Nonaka K, *et al*. Dose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus. *Endocr J* 2010;57:383–94.
- Moritoh Y, Takeuchi K, Hazama M. Chronic Administration of Voglibose, an α -Glucosidase Inhibitor, Increases Active Glucagon-Like Peptide-1 Levels by Increasing Its Secretion and Decreasing Dipeptidyl Peptidase-4 Activity in ob/ob Mice. *J Pharmacol Exp Ther* 2009;329:669–76.
- Ranganath LMV. Delayed gastric emptying occurs following acarbose administration and is a further mechanism for its anti-hyperglycaemic effect. *Diabet Med* 1998;15:120–4.
- [No authors listed]. Report of the expert committee on the diagnosis and classification of diabetes mellitus. *Diabetes Care* 1997;20:1183–97.
- Japanese Society of Nephrology, ed. *Clinical practice guidebook for diagnosis and treatment of chronic kidney disease 2012*. Tokyo: Tokyo-igakusha, 2012.
- Horio M. [Development of evaluation of kidney function and classification of chronic kidney disease (CKD)—including CKD clinical practice guide 2012]. *Rinsho Byori* 2013;61:616–21.
- Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. *Diabetes Care* 2004;27:1487–95.
- Iwata M, Maeda S, Kamura Y, *et al*. Genetic risk score constructed using 14 susceptibility alleles for type 2 diabetes is associated with the early onset of diabetes and may predict the future requirement of insulin injections among Japanese individuals. *Diabetes Care* 2012;35:1763–70.
- Matthews DR, Hosker JP, Rudenski AS, *et al*. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. *Diabetologia* 1985;28:412–19.
- Yamada Y, Fukuda K, Fujimoto S, *et al*. SUIT, secretory units of islets in transplantation: an index for therapeutic management of islet transplanted patients and its application to type 2 diabetes. *Diabetes Res Clin Pract* 2006;74:222–6.
- Katz A. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. *J Clin Endocrinol Metab* 2000;85:2402–10.
- Corpeleijn E, Feskens EJM, Jansen EHJM, *et al*. Improvements in glucose tolerance and insulin sensitivity after lifestyle intervention are related to changes in serum fatty acid profile and desaturase activities: the SLIM study. *Diabetologia* 2006;49:2392–401.
- Nonaka K, Kakikawa T, Sato A, *et al*. Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes. *Diabetes Res Clin Pract* 2008;79:291–8.
- Iwamoto Y, Tajima N, Kadowaki T, *et al*. Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial. *Diabetes Obes Metab* 2010;12:613–22.
- Cai X, Han X, Luo Y, *et al*. Efficacy of dipeptidyl-peptidase-4 inhibitors and impact on β -cell function in Asian and Caucasian type 2 diabetes mellitus patients: a meta-analysis. *J Diabetes* 2015;7:347–59.
- Holst JJ, Deacon CF. Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus. *Curr Opin Pharmacol* 2004;4:589–96.
- Holst JJ, Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. *Am J Physiol Endocrinol Metab* 2004;287:E199–206.
- Pospisilik JA, Martin J, Doty T, *et al*. Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. *Diabetes* 2003;52:741–50.
- Gerich J. DPP-4 inhibitors: what may be the clinical differentiators? *Diabetes Res Clin Pract* 2010;90:131–40.
- Pratley RE, Schweizer A, Rosenstock J, *et al*. Robust improvements in fasting and prandial measures of beta-cell function with

- vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database. *Diabetes, Obes Metab* 2008;10:931–8.
26. Charbonnel B, Karasik A, Liu J, *et al*. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. *Diabetes Care* 2006;29:2638–43.
 27. Aso Y, Fukushima M, Sagara M, *et al*. Sitagliptin, a DPP-4 inhibitor, alters the subsets of circulating CD4+ T cells in patients with type 2 diabetes. *Diabetes Res Clin Pract* 2015;110:250–6.
 28. Kubota A, Maeda H, Kanamori A, *et al*. Pleiotropic effects of sitagliptin in the treatment of type 2 diabetes mellitus patients. *J Clin Med Res* 2012;4:309–13.
 29. Arjona Ferreira JC, Marre M, Barzilai N, *et al*. Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency. *Diabetes Care* 2013;36:1067–73.
 30. Aschner P, Kipnes MS, Lunceford JK, *et al*. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. *Diabetes Care* 2006;29:2632–7.
 31. Seo C, Sakamoto M, Nishimura R, *et al*. Comparison of glycemic variability in patients with type 2 diabetes given sitagliptin or voglibose: a continuous glucose monitoring-based pilot study. *Diabetes Technol Ther* 2013;15:378–85.
 32. Kubota Y, Miyamoto M, Takagi G, *et al*. The dipeptidyl peptidase-4 inhibitor sitagliptin improves vascular endothelial function in type 2 diabetes. *J Korean Med Sci* 2012;27:1364–70.
 33. Fujitaka K, Otani H, Jo F, *et al*. Comparison of metabolic profile and adiponectin level with pioglitazone versus voglibose in patients with type-2 diabetes mellitus associated with metabolic syndrome. *Endocr J* 2011;58:425–32.
 34. Fisman EZ, Tenenbaum A. Adiponectin: a manifold therapeutic target for metabolic syndrome, diabetes, and coronary disease? *Cardiovasc Diabetol* 2014;13:103.
 35. Senmaru T, Fukui M, Kobayashi K, *et al*. Dipeptidyl-peptidase IV inhibitor is effective in patients with type 2 diabetes with high serum eicosapentaenoic acid concentrations. *J Diabetes Investig* 2012;3:498–502.
 36. Inoue I, Shinoda Y, Nakano T, *et al*. Acarbose ameliorates atherogenicity of low-density lipoprotein in patients with impaired glucose tolerance. *Metab Clin Exp* 2006;55:946–52.
 37. Vessby B, Gustafsson I-B, Tengblad S, *et al*. Desaturation and elongation of Fatty acids and insulin action. *Ann N Y Acad Sci* 2002;967:183–95.
 38. Warensjö E, Rosell M, Hellenius M-L, *et al*. Associations between estimated fatty acid desaturase activities in serum lipids and adipose tissue in humans: links to obesity and insulin resistance. *Lipids Health Dis* 2009;8:37.
 39. Kröger J, Schulze MB. Recent insights into the relation of $\Delta 5$ desaturase and $\Delta 6$ desaturase activity to the development of type 2 diabetes. *Curr Opin Lipidol* 2012;23:4–10.
 40. Mayneris-Perxachs J, Guerediain M, Castellote AI, *et al*. Plasma fatty acid composition, estimated desaturase activities, and their relation with the metabolic syndrome in a population at high risk of cardiovascular disease. *Clin Nutr* 2014;33:90–7.
 41. Lu Y, Vaarhorst A, Merry AHH, *et al*. Markers of endogenous desaturase activity and risk of coronary heart disease in the CAREMA cohort study. *PLoS ONE* 2012;7:e41681.